ReviewCurrent opinion in allergy and clinical immunology2017
Component resolved diagnostics for hymenoptera venom allergy.
Review in Current opinion in allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 76 citations in OpenAlex.
- Protocols for Diagnosis and Management of Arthropod Bite Allergies in Humans.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Article
- In vitro diagnostics in hymenoptera venom allergy: Current concepts and perspectives.Allergologie select · 2026Review
- Evolution of Phospholipase A2 in Bees and Flies.Ecology and evolution · 2025Article
- Molecular allergens drive risk stratification and immunotherapy in Hymenoptera venom allergy.The World Allergy Organization journal · 2025Article
- Article
- Validation of a Multiplex Molecular Macroarray for the Determination of Allergen-Specific IgE Sensitizations in Dogs.Veterinary sciences · 2024Article
- The role of molecular diagnosis in anaphylactic patients with dual or triple-sensitization to Hymenoptera venoms.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Article
- Potential and limitations of epitope mapping and molecular targeting in Hymenoptera venom allergy.Frontiers in allergy · 2023Review
- Diagnosis ofBiomedicines · 2022Review
- Article
- Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management.Clinical reviews in allergy & immunology · 2022Review
- Article
- Integration of in vitro allergy test results and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA).Clinical and translational allergy · 2021Review
- Precision medicine reaching out to the patients in allergology - a German-Japanese workshop report.Allergologie select · 2021Article
- Itch in Hymenoptera Sting Reactions.Frontiers in allergy · 2021Article
- Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy.Current allergy and asthma reports · 2020Review
- The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy.Current allergy and asthma reports · 2020Review
- Functional Profile of Antigen Specific CD4Toxins · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewComponent-resolved diagnostics makes use of defined allergen molecules to analyse IgE-mediated sensitizations at a molecular level. Here, we review recent studies on the use of component-resolved diagnostics in the field of Hymenoptera venom allergy (HVA) and discuss its benefits and limitations. RECENT
findingsComponent resolution in HVA has moved from single molecules to panels of allergens. Detection of specific immunoglobulin E (sIgE) to marker and cross-reactive venom allergens has been reported to facilitate the discrimination between primary sensitization and cross-reactivity and thus, to provide a better rationale for prescribing venom immunotherapy (VIT), particularly in patients sensitized to both honeybee and vespid venom. Characterization of IgE reactivity to a broad panel of venom allergens has allowed the identification of different sensitization profiles that in honeybee venom allergy were associated with increased risks for side effects or treatment failure of VIT. In contrast, component resolution so far has failed to provide reliable markers for the discrimination of sensitizations to venoms of different members of Vespidae. SUMMARY: Component-resolved diagnostics allows a better understanding of the complexity of sensitization and cross-reactivities in HVA. In addition, the enhanced resolution and precision may allow identification of biomarkers, which can be used for risk stratification in VIT. Knowledge about the molecular composition of different therapeutic preparations may enable the selection of appropriate preparations for VIT according to individual sensitization profiles, an approach consistent with the goals of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.